Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.68 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.68 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CD74 | P04233 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70173 | 0.85 | CYP4F2 (0.83) | CYP4F2CYP4A11LOXL2MEN1KMT2A | |
| SCHEMBL3995781 | 0.85 | CYP4F2 (0.66) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL14037038 | 0.85 | CYP4F2 (0.68) | CYP4F2CYP4A11LOXL2MEN1KMT2A | |
| SCHEMBL29539688 | 0.84 | LOXL2 (0.64) | CYP4F2CYP4A11LOXL2MEN1KMT2A | |
| SCHEMBL40562 | 0.84 | LOXL2 (0.64) | CYP4F2CYP4A11LOXL2MEN1KMT2A | |
| SCHEMBL10784559 | 0.84 | KMT2A (0.51) | CYP4F2CYP4A11LOXL2MEN1KMT2A | |
| SCHEMBL17844265 | 0.83 | MRGPRX4 (0.56) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 | |
| SCHEMBL6459667 | 0.83 | MEN1 (0.61) | CYP4F2CYP4A11MEN1KMT2AMRGPRX4 | |
| SCHEMBL27676657 | 0.81 | CYP4F2 (0.60) | CYP4F2CYP4A11MEN1KMT2AALDH1A1 | |
| SCHEMBL46931 | 0.81 | CYP4A11 (1.00) | CYP4F2CYP4A11LOXL2SLC7A5MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111675631-A | Synthesis process of cyano ketoprofen | 湖北仙盛科技股份有限公司 | 2020-09-18 | — | — | CN | claimed |
| WO-2023227666-A1 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | WO | disclosed |
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | H. Lee Moffitt Cancer Center and Research Center Institute, Inc. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | H. Lee Moffitt Cancer Center and Research Center Institute, Inc. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2022-02-22 | — | — | US | disclosed |
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-01-21 | — | — | US | disclosed |
| CN-111675631-A | Synthesis process of cyano ketoprofen | 湖北仙盛科技股份有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-20200207721-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2020-07-02 | — | — | US | disclosed |
| WO-2019191410-A1 | INHIBITORS FOR THE Β-CATENIN / T-CELL FACTOR PROTEIN–PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | US | disclosed |
| WO-2016030534-A1 | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2016-03-03 | — | — | WO | disclosed |
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2049541-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016192-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
| US-4656233-A | \"Living\" polymers and chain transfer-regulated polymerization process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
| EP-0186330-A1 | \"Living\" polymers and chain transfer-regulated polymerization process | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017139-A1 | INHIBITORS FOR THE B-CATENIN / T-CELL FACTOR PROTEIN-PROTEIN INTERACTION | CTNNBL1, CTNNB1, APC | CYP4F2 3958/4885CYP4A11 3295/4885LOXL2 3185/4885 |
| US-20200207721-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | CYP4F2 1618/4885CYP4A11 2498/4885LOXL2 1982/4885 |
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | CTNNB1, CTNNBL1, APC | CYP4F2 4063/4885CYP4A11 3426/4885LOXL2 2856/4885 |
| US-20160060226-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | CYP4F2 1618/4885CYP4A11 2498/4885LOXL2 1982/4885 |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | CYP4F2 770/4885CYP4A11 434/4885LOXL2 2727/4885 |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | CYP4F2 1618/4885CYP4A11 2498/4885LOXL2 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.